Short Commercial Route to GSK’s HIV Protease Inhibitor Brecanavir

GSK have developed a short route to their drug Brecanavir in 73% yield over 4 steps with only 1 intermediate isolation The key intermediate bis-tetrahydrofuran was made via several routes including two photochemical approaches.

Click on the link on the right to download a PDF of the complete Newsletter